{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:48:32Z","timestamp":1792093712527,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10461-025-04741-8","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:45:42Z","timestamp":1746492342000},"page":"2841-2854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Performance of Adherence Measures for Oral, Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Systematic Review"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2045-765X","authenticated-orcid":false,"given":"Diana","family":"Zeballos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0487-0500","authenticated-orcid":false,"given":"Nathalia Sernizon","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-2502","authenticated-orcid":false,"given":"Marcos","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3752-0782","authenticated-orcid":false,"given":"Laio","family":"Magno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-2146","authenticated-orcid":false,"given":"In\u00eas","family":"Dourado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"4741_CR1","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587\u201399.","journal-title":"N Engl J Med"},{"key":"4741_CR2","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","volume":"30","author":"VA Fonner","year":"2016","unstructured":"Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O\u2019Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30:1973\u201383.","journal-title":"AIDS"},{"key":"4741_CR3","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","volume":"14","author":"RM Grant","year":"2014","unstructured":"Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820\u20139.","journal-title":"Lancet Infect Dis"},{"key":"4741_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12879-018-3463-4","volume":"18","author":"D Sidebottom","year":"2018","unstructured":"Sidebottom D, Ekstr\u00f6m AM, Str\u00f6mdahl S. A systematic review of adherence to oral pre-exposure prophylaxis for HIV\u2014how can we improve uptake and adherence? BMC Infect Dis. 2018;18:581.","journal-title":"BMC Infect Dis"},{"key":"4741_CR5","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/QAD.0000000000001385","volume":"31","author":"AS Nunn","year":"2017","unstructured":"Nunn AS, Brinkley-Rubinstein L, Oldenburg CE, Mayer KH, Mimiaga M, Patel R, et al. Defining the HIV pre-exposure prophylaxis care continuum. AIDS. 2017;31:731\u20134.","journal-title":"AIDS"},{"key":"4741_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/COH.0000000000000220","volume":"11","author":"JE Haberer","year":"2016","unstructured":"Haberer JE. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Curr Opin HIV AIDS. 2016;11:10\u20137.","journal-title":"Curr Opin HIV AIDS"},{"key":"4741_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26103","volume":"26","author":"C Celum","year":"2023","unstructured":"Celum C, Grinsztejn B, Ngure K. Preparing for long-acting PrEP delivery: building on lessons from oral PrEP. J Int AIDS Soc. 2023;26: e26103.","journal-title":"J Int AIDS Soc"},{"key":"4741_CR8","doi-asserted-by":"publisher","first-page":"20222","DOI":"10.7448\/IAS.18.4.20222","volume":"18","author":"CF C\u00e1ceres","year":"2015","unstructured":"C\u00e1ceres CF, O\u2019Reilly KR, Mayer KH, Baggaley R. PrEP implementation: moving from trials to policy and practice. J Int AIDS Soc. 2015;18:20222.","journal-title":"J Int AIDS Soc"},{"key":"4741_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/PPA.S248696","volume":"15","author":"A Hannaford","year":"2021","unstructured":"Hannaford A, Arens Y, Koenig H. Real-time monitoring and point-of-care testing: a review of the current landscape of PrEP adherence monitoring. Patient Prefer Adherence. 2021;15:259\u201369.","journal-title":"Patient Prefer Adherence"},{"key":"4741_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487\u201397.","journal-title":"N Engl J Med"},{"key":"4741_CR11","doi-asserted-by":"publisher","first-page":"e01710","DOI":"10.1128\/AAC.01710-17","volume":"62","author":"PL Anderson","year":"2018","unstructured":"Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2018;62:e01710-e1717.","journal-title":"Antimicrob Agents Chemother"},{"key":"4741_CR12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/aid.2012.0089","volume":"29","author":"JR Castillo-Mancilla","year":"2013","unstructured":"Castillo-Mancilla JR, Zheng J-H, Rower JE, Meditz A, Gardner EM, Predhomme J, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29:384\u201390.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"4741_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/QAI.0000000000000172","volume":"66","author":"D Donnell","year":"2014","unstructured":"Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66:340\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4741_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s13142-015-0315-2","volume":"5","author":"MJ Stirratt","year":"2015","unstructured":"Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, et al. Self-report measures of medication adherence behavior: Recommendations on optimal use. Transl Behav Med. 2015;5:470\u201382.","journal-title":"Transl Behav Med"},{"key":"4741_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3851\/IMP3346","volume":"25","author":"B Baranek","year":"2020","unstructured":"Baranek B, Wang S, Cheung AM, Mishra S, Tan DHS. The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis. Antivir Ther. 2020;25:21\u201332.","journal-title":"Antivir Ther"},{"key":"4741_CR16","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.2023.9865","volume":"330","author":"R Chou","year":"2023","unstructured":"Chou R, Spencer H, Bougatsos C, Blazina I, Ahmed A, Selph S. Preexposure prophylaxis for the prevention of HIV: updated evidence report and systematic review for the US preventive services task force. JAMA. 2023;330:746\u201363.","journal-title":"JAMA"},{"key":"4741_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S2055-6640(20)30312-5","volume":"4","author":"V Pilkington","year":"2018","unstructured":"Pilkington V, Hill A, Hughes S, Nwokolo N, Pozniak A. How safe is TDF\/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. J Virus Erad. 2018;4:215\u201324.","journal-title":"J Virus Erad"},{"key":"4741_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S2352-3018(22)00004-2","volume":"9","author":"R Schaefer","year":"2022","unstructured":"Schaefer R, da Costa A, Leite PH, Silva R, Abdool Karim Q, Akolo C, C\u00e1ceres CF, et al. Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data. Lancet HIV. 2022;9:242\u201353.","journal-title":"Lancet HIV"},{"key":"4741_CR19","first-page":"115","volume":"2016","author":"R Yacoub","year":"1988","unstructured":"Yacoub R, Nadkarni GN, Weikum D, Konstantinidis I, Boueilh A, Grant RM, et al. Elevations in serum creatinine with tenofovir-based HIV pre-exposure prophylaxis: a meta-analysis of randomized placebo-controlled trials. J Acquir Immune Defic Syndr. 1988;2016:115\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4741_CR20","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00030-3","volume":"9","author":"J Zhang","year":"2022","unstructured":"Zhang J, Li C, Xu J, Hu Z, Rutstein SE, Tucker JD, et al. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. Lancet HIV. 2022;9:e254\u201368.","journal-title":"Lancet HIV"},{"key":"4741_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"4741_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529\u201336.","journal-title":"Ann Intern Med"},{"key":"4741_CR23","doi-asserted-by":"publisher","first-page":"0221281","DOI":"10.1371\/journal.pone.0221281","volume":"14","author":"LMS Marins","year":"2019","unstructured":"Marins LMS, Torres TS, da Leite I, Moreira C, Luz RI, Hoagland PM, et al. Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: results from the PrEP BrasIL study. PLoS One. 2019;14:0221281.","journal-title":"PLoS One"},{"key":"4741_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/apc.2020.0005","volume":"34","author":"AA Leech","year":"2020","unstructured":"Leech AA, Biancarelli D, Aaron E, Miller ES, Coleman JS, Anderson PL, et al. HIV pre-exposure prophylaxis for conception among HIV serodiscordant couples in the United States: a cohort study. AIDS Patient Care STDS. 2020;34:295\u2013302.","journal-title":"AIDS Patient Care STDS"},{"key":"4741_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157742","volume":"11","author":"MC Montgomery","year":"2016","unstructured":"Montgomery MC, Oldenburg CE, Nunn AS, Mena L, Anderson P, Liegler T, et al. Adherence to pre-exposure prophylaxis for HIV prevention in a clinical setting. PLoS ONE. 2016;11: e0157742.","journal-title":"PLoS ONE"},{"key":"4741_CR26","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1007\/s10461-017-1958-4","volume":"22","author":"Z Baker","year":"2018","unstructured":"Baker Z, Javanbakht M, Mierzwa S, Pavel C, Lally M, Zimet G, et al. Predictors of over-reporting HIV pre-exposure prophylaxis (PrEP) adherence among young men who have sex with men (YMSM) in self-reported versus biomarker data. AIDS Behav. 2018;22:1174\u201383.","journal-title":"AIDS Behav"},{"key":"4741_CR27","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3389\/fphar.2019.00721","volume":"10","author":"J Blumenthal","year":"2019","unstructured":"Blumenthal J, Pasipanodya EC, Jain S, Sun S, Ellorin E, Morris S, et al. Comparing self-report pre-exposure prophylaxis adherence questions to pharmacologic measures of recent and cumulative pre-exposure prophylaxis exposure. Front Pharmacol. 2019;10:721.","journal-title":"Front Pharmacol"},{"key":"4741_CR28","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s10461-022-03860-w","volume":"27","author":"SM Graham","year":"2023","unstructured":"Graham SM, Okall DO, Mehta SD, Obondi E, Ng\u2019ety G, Ochieng E, et al. Challenges with PrEP uptake and adherence among gay, bisexual, and other men who have sex with men in Kisumu Kenya. AIDS Behav. 2023;27:1234\u201347.","journal-title":"AIDS Behav"},{"key":"4741_CR29","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1007\/s10461-016-1406-x","volume":"20","author":"IB Wilson","year":"2016","unstructured":"Wilson IB, Lee Y, Michaud J, Fowler FJ, Rogers WH. Validation of a new three-item self-report measure for medication adherence. AIDS Behav. 2016;20:2700\u20138.","journal-title":"AIDS Behav"},{"key":"4741_CR30","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1097\/QAD.0000000000003617","volume":"37","author":"J Pintye","year":"2023","unstructured":"Pintye J, Kinuthia J, Abuna F, Anderson PL, Dettinger JC, Gomez L, et al. HIV pre-exposure prophylaxis initiation, persistence, and adherence during pregnancy through the postpartum period. AIDS. 2023;37:1725\u201337.","journal-title":"AIDS"},{"key":"4741_CR31","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1007\/s10461-023-04111-2","volume":"27","author":"N Musinguzi","year":"2023","unstructured":"Musinguzi N, Ngure K, Bukusi EA, Mugo NR, Baeten JM, Anderson PL, et al. Performance of multiple adherence measures for pre-exposure prophylaxis (PrEP) among young women in Kenya. AIDS Behav. 2023;27:3961\u20139.","journal-title":"AIDS Behav"},{"key":"4741_CR32","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1097\/QAD.0000000000003710","volume":"37","author":"B Mustanski","year":"2023","unstructured":"Mustanski B, Ryan DT, Spinelli MA, Gandhi M, Newcomb ME. Urine point-of-care tenofovir test demonstrates strong predictive clinical and research utility. AIDS. 2023;37:2381\u20137.","journal-title":"AIDS"},{"key":"4741_CR33","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s10461-022-03826-y","volume":"27","author":"A Townes","year":"2023","unstructured":"Townes A, Pyra M, Smith DK, Babu AS, Williams T, Wiener J, et al. PrEP use and adherence among transgender persons in Chicago, IL (SHIPP study, 2014\u20132018, USA). AIDS Behav. 2023;27:901\u20138.","journal-title":"AIDS Behav"},{"key":"4741_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104284","volume":"123","author":"K Dumchev","year":"2024","unstructured":"Dumchev K, Kornilova M, Makarenko O, Antoniak S, Liulchuk M, Cottrell ML, et al. Low daily oral PrEP adherence and low validity of self-report in a randomized trial among PWID in Ukraine. Int J Drug Policy. 2024;123: 104284.","journal-title":"Int J Drug Policy"},{"key":"4741_CR35","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1097\/QAD.0000000000001955","volume":"32","author":"N Musinguzi","year":"2018","unstructured":"Musinguzi N, Muwonge T, Ngure K, Katabira E, Mugo N, Burns BFO, et al. Comparison of short messaging service self-reported adherence with other adherence measures in a demonstration project of HIV preexposure prophylaxis in Kenya and Uganda. AIDS. 2018;32:2237\u201345.","journal-title":"AIDS"},{"key":"4741_CR36","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/QAD.0000000000001024","volume":"30","author":"N Musinguzi","year":"2016","unstructured":"Musinguzi N, Muganzi CD, Boum Y 2nd, Ronald A, Marzinke MA, Hendrix CW, et al. Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa. AIDS. 2016;30:1121\u20139.","journal-title":"AIDS"},{"key":"4741_CR37","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s10461-014-0891-z","volume":"19","author":"P Kebaabetswe","year":"2015","unstructured":"Kebaabetswe P, Stirratt MJ, McLellan-Lemal E, Henderson F, Gray S, Rose C, et al. Factors associated with adherence and concordance between measurement strategies in an HIV daily oral tenofovir\/emtricitibine as pre-exposure prophylaxis (Prep) clinical trial, Botswana, 2007\u20132010. AIDS Behav. 2015;19:758\u201369.","journal-title":"AIDS Behav"},{"key":"4741_CR38","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s10461-016-1360-7","volume":"20","author":"KR Amico","year":"2016","unstructured":"Amico KR, Mehrotra M, Avelino-Silva VI, Mcmahan VM, Veloso VG, Anderson PL, et al. Self-reported recent PrEP dosing and drug detection in an open label PrEP study. AIDS Behav. 2016;20:1535\u201340.","journal-title":"AIDS Behav"},{"key":"4741_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282999","volume":"18","author":"OA Adeyemi","year":"2023","unstructured":"Adeyemi OA, Nowak RG, Marzinke M, Morgan D, Sam-Agudu N, Craddock J, et al. Correlates of self-reported and biomarker based adherence to daily oral HIV pre-exposure prophylaxis among a cohort of predominantly men who have sex with men in Nigeria. PLoS ONE. 2023;18: e0282999.","journal-title":"PLoS ONE"},{"key":"4741_CR40","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s10461-014-0859-z","volume":"19","author":"K Agot","year":"2015","unstructured":"Agot K, Taylor D, Corneli AL, Wang M, Ambia J, Kashuba ADM, et al. Accuracy of self-report and pill-count measures of adherence in the FEM-PrEP clinical trial: Implications for future HIV-prevention trials. AIDS Behav. 2015;19:743\u201351.","journal-title":"AIDS Behav"},{"key":"4741_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.19.1.20642","volume":"19","author":"A van der Straten","year":"2016","unstructured":"van der Straten A, Brown ER, Marrazzo JM, Chirenje MZ, Liu K, Gomez K, et al. Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study. J Int AIDS Soc. 2016;19:1\u201310.","journal-title":"J Int AIDS Soc"},{"key":"4741_CR42","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1097\/QAD.0000000000002618","volume":"34","author":"M Pyra","year":"2020","unstructured":"Pyra M, Rusie L, Castro M, Keglovitz Baker K, McNulty M, Bohm N, et al. A taxonomy of pragmatic measures of HIV preexposure prophylaxis use. AIDS. 2020;34:1951\u20137.","journal-title":"AIDS"},{"key":"4741_CR43","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1097\/QAI.0000000000002854","volume":"89","author":"PR Chai","year":"2022","unstructured":"Chai PR, Mohamed Y, Bustamante MJ, Goodman GR, Najarro J, Castillo-mancilla J, et al. DigiPrEP: a pilot trial to evaluate the feasibility, acceptability, and accuracy of a digital pill system to measure PrEP adherence in men who have sex with men who use substances. J Acquir Immune Defic Syndr. 2022;89:e5-15.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4741_CR44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/QAI.0000000000002128","volume":"82","author":"J Velloza","year":"2019","unstructured":"Velloza J, Bacchetti P, Hendrix CW, Murnane P, Hughes JP, Li M, et al. Short- and long-term pharmacologic measures of HIV pre-exposure prophylaxis use among high-risk men who have sex with men in HPTN 067\/ADAPT. J Acquir Immune Defic Syndr. 2019;82:149\u201358.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4741_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004088","author":"LT Matthews","year":"2023","unstructured":"Matthews LT, Atukunda EC, Owembabazi M, Kalyebera KP, Psaros C, Chitneni P, et al. High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: a cohort study. PLoS Med. 2023. https:\/\/doi.org\/10.1371\/journal.pmed.1004088.","journal-title":"PLoS Med."},{"key":"4741_CR46","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1001\/jama.2024.0464","volume":"331","author":"J Marrazzo","year":"2024","unstructured":"Marrazzo J, Tao L, Becker M, Leech AA, Taylor AW, Ussery F, et al. HIV preexposure prophylaxis with emtricitabine and tenofovir disoproxil fumarate among cisgender women. JAMA. 2024;331:930\u20137.","journal-title":"JAMA"},{"key":"4741_CR47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/infdis\/jiw077","volume":"214","author":"ML Cottrell","year":"2016","unstructured":"Cottrell ML, Yang KH, Prince HMA, Sykes C, White N, Malone S, et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016;214:55\u201364.","journal-title":"J Infect Dis"},{"key":"4741_CR48","first-page":"2024","volume-title":"Adherence and HIV protection thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among\u00a0Cisgender Women: a systematic review","author":"L Wu","year":"2024","unstructured":"Wu L, Niu X, Brunelli MK, Mugwanya KK. Adherence and HIV protection thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among\u00a0Cisgender Women: a systematic review. Berlin: Springer; 2024. p. 2024."},{"key":"4741_CR49","unstructured":"WHO. WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. Module 3: Counsellors. Geneva; 2017. http:\/\/apps.who.int\/bookorders."},{"key":"4741_CR50","unstructured":"WHO. WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. Module 6: Pharmacists. Geneva. 2017. http:\/\/apps.who.int\/bookorders."},{"key":"4741_CR51","unstructured":"CDC. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection IN, The United States. 2021 Update, a clinical practice guideline. 2021."},{"key":"4741_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5527","author":"PM Bossuyt","year":"2015","unstructured":"Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015-An updated list of essential items for reporting diagnostic accuracy studies copying with attribution allowed for any non-commercial use of the work (creative commons license CC BY-NC 40). BMJ. 2015. https:\/\/doi.org\/10.1136\/bmj.h5527.","journal-title":"BMJ"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04741-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-025-04741-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04741-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T16:01:59Z","timestamp":1757692919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-025-04741-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["4741"],"URL":"https:\/\/doi.org\/10.1007\/s10461-025-04741-8","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"19 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}